Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Oncology

Neither a doctor nor a teaching hospital

Research payments

$12,217,629

1,996 payments

Through program year 2025, Texas Oncology is reported as receiving $12,217,629 in research payments, across 1,996 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $616,773 206
2024 Research $598,736 50
2023 Research $2,037,566 129
2022 Research $1,310,066 421
2021 Research $1,957,929 675
2020 Research $2,929,758 309
2019 Research $2,766,800 206

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $5,920,918 437 payments
  2. Novartis Pharmaceuticals Corporation $3,519,511 86 payments
  3. Incyte Corporation $1,521,675 996 payments
  4. Merck Sharp & Dohme Corporation $285,445 36 payments
  5. GlaxoSmithKline, LLC. $280,685 50 payments
  6. Celgene Corporation $190,617 67 payments
  7. Jazz Pharmaceuticals Inc. $188,348 158 payments
  8. Amgen Inc. $90,359 24 payments
  9. Daiichi Sankyo Inc. $45,645 24 payments
  10. BeiGene, Ltd. $37,584 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Phase III Study, Comparing Nis793 in Combination With Gemcitabine and Nab-Paclitaxel Versus (VS.) Placebo Combined With Gemcitabine and Nab-Paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac) $1,702,983 3 payments
  2. Phase II III 1L CRC Nivo CT w pt segmentation rational combos $690,421 10 payments
  3. Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $540,039 710 payments
  4. Phase III 1L Metastatic RCC Nivo Ipi Cabo $489,263 11 payments
  5. Phase IIIA FIH Nivo Combo Study $446,959 5 payments
  6. Phase IIIII 1L CRC NivoCT wpt segmentationrational combos $425,059 5 payments
  7. Patient Journey, Treatment Patterns, and Clinical Outcomes of Women Diagnosed With HR+/HER2 Early-Stage Breast Cancer $397,285 2 payments
  8. A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected Tki in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase $377,663 4 payments
  9. A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy $369,589 49 payments
  10. Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (MF) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy $336,975 84 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $1,250 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record